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Abstract
Background: A method for inhibiting the expression of particular genes using external guide
sequences (EGSs) has been developed in bacteria, mammalian cells and maize cells.
Results: To examine whether EGS technology can be used to down-regulate gene expression in
Caenorhabditis elegans (C. elegans), we generated EGS-Ngfp-lacZ and EGS-Mtgfp that are targeted
against Ngfp-lacZ and Mtgfp mRNA, respectively. These EGSs were introduced, both separately and
together, into the C. elegans strain PD4251, which contains Ngfp-lacZ and Mtgfp. Consequently, the
expression levels of Ngfp-lacZ  and  Mtgfp  were affected by EGS-Ngfp-lacZ and EGS-Mtgfp,
respectively. We further generated an EGS library that contains a randomized antisense domain of
tRNA-derived EGS ("3/4 EGS"). Examination of the composition of the EGS library showed that
there was no obvious bias in the cloning of certain EGSs. A subset of EGSs was randomly chosen
for screening in the C. elegans strain N2. About 6% of these EGSs induced abnormal phenotypes
such as P0 slow postembryonic growth, P0 larval arrest, P0 larval lethality and P0 sterility. Of these,
EGS-35 and EGS-83 caused the greatest phenotype changes, and their target mRNAs were
identified as ZK858.7 mRNA and Lin-13 mRNA, respectively.
Conclusion: EGS technology can be used to down-regulate gene expression in C. elegans. The EGS
library is a research tool for reverse genetic screening in C. elegans. These observations are
potentially of great importance to further our understanding and use of C. elegans genomics.
Background
RNase P catalyzes the maturation of 5'-termini of all
tRNAs by a single endonucleolytic cleavage of their pre-
cursors[1]. This enzyme is found in cells from all three
domains of life: the Bacteria, Eukaryote and Archaea [2-5].
One of the unique features of RNase P is its ability to rec-
ognize the structures, rather than the sequences, of tRNAs;
this allows the enzyme to cleave other substrates with sim-
ilar structure to the tRNA precursor. Accordingly, any
complex of two RNA molecules that resembles a similar
tRNA molecule can be recognized and cleaved by RNase P
[6-8]. One of the two RNA molecules that resemble the
complex is termed the external guide sequence (EGS). In
principle, an mRNA sequence can be targeted for RNase P
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cleavage by hybridization with EGS to direct RNase P to
the cleavage site. Subsequent studies have shown that EGS
technology can be used to down-regulate gene expression
in many organisms, such as bacteria, [9-12] mammalian
cells [13-19]and maize cells[20].
Nucleic-acid-based gene-interference strategies, such as
anti-sense oligonucleotides, ribozymes, and RNAi, are
powerful research tools and promising therapeutic agents
for human diseases [21-25]. Each technology has advan-
tages and limitations in terms of targeting efficacy and
specificity [26]. Compared with other nucleic-acid-based
gene-interference strategies, such as the RNAi approach
that induces the cellular RISC RNase to cleave a target
mRNA [26,27], targeted cleavage of mRNA by RNase P
using an EGS is a unique approach that can be used to
inactivate any RNA of known sequence expressed in vivo.
Moreover two types of interaction govern the targeting
specificity of EGS[3,19]. One is the Watson-Crick base-
pairing interaction between the anti-sense domain of an
EGS and the accessible region of a target mRNA. The other
is the interaction between a target mRNA and the other
domains of an EGS, which are required for folding of the
RNase P-recognizable tertiary structure.
Several EGSs derived from natural tRNA sequences have
been shown to be effective in blocking gene expression in
bacteria[12,28] and mammalian cells[29]. For example,
the "3/4 EGS" resembles three-quarters of the tRNA mol-
ecule and consists of two sequence elements: a targeting
sequence that is complementary to the accessible region
of a target mRNA in which most sequences are inaccessi-
ble owing to the secondary or tertiary structures of the
RNA and or the binding of proteins; and a RNase-P-recog-
nizing sequence that is a portion of the tRNA sequence
and required for interacting with RNase P[8]. It has been
demonstrated that the "3/4 EGS" effectively and specifi-
cally induces target mRNA cleavage by eukaryotic RNase P
[8,28].
Phenotype changes have been associated with more than
1,500 C. elegans genes through a combination of RNAi
screens, classical mutant screens and systematic gene
knockout experiments [30-42]. Despite these successes,
the functions of most of the approximately 20,000 pre-
dicted genes in the C. elegans genome remain elusive.
Moreover, there were some clear differences in the results
of these RNAi screens conducted by different researchers.
These differences were considered to result from different
approaches and standards in RNAi screening. Further-
more, there was also 10 to 30% variability in the results of
the RNAi screens conducted by the same researcher
according to the same procedure [30,31,34,36-40,43,44].
The relative variability of the RNAi effect should be an
important consideration before the RNAi data are used as
starting point for new experiments[40]. In this study, we
show that EGS technology can be used to down-regulate
gene expression in C. elegans, and the EGS library can
facilitate a reverse genetic screen similar to that possible
with an RNAi library
Results
Validation of EGS technology for down-regulating gene 
expression in C. elegans
There are two types of green fluorescent proteins (GFP) in
C. elegans strain PD4251. Ngfp consists of a wild-type GFP
and a nuclear-localization signal encoded by Ngfp-lacZ.
Mtgfp consists of a wild-type GFP and a mitochondrial-
localization signal encoded by Mtgfp[45]. EGSs that target
to Ngfp-lacZ or Mtgfp mRNA can be designed using RNA-
folding software[46]. According to the rules of EGS
design[28], the favorable accessible regions of Ngfp-lacZ
(Fig. 1A) and Mtgfp mRNAs (Fig. 1B) were identified from
all candidate accessible regions. The "3/4 EGS" (Fig. 1C)
was used as the framework. The anti-sense sequence of the
accessible region was introduced into the antisense
domain of the framework. The "CCA"
sequence[7,8,28,47,48] located in the 3'-terminus is
important for the EGS effect. To protect the "CCA"
sequence from being exposed directly to RNase, the
"UUU" sequence was attached to its 3'-terminus. Two
EGSs, EGS-Ngfp-lacZ (Fig. 1D) and EGS-Mtgfp (Fig. 1F),
were constructed. Two additional EGSs, EGS-Ngfp-lacZ-D
(Fig. 1E) and EGS-Mtgfp-D (Fig. 1G), were also con-
structed. EGS-Ngfp-lacZ-D and EGS-Mtgfp-D were
derived from EGS-Ngfp-lacZ and EGS-Mtgfp, respectively,
and contained point mutations (5'-TTC-3' → AAG) at the
three highly conserved positions in the "T-loop" of these
EGSs. These nucleotides have been found in most of the
known, natural tRNA sequences[49] and are thought to be
important for interactions between the tRNA domains
and human RNase P[3]. Previous studies have shown that
EGSs with these mutations prevented RNase P recognition
and showed little activity in directing RNase-P-mediated
cleavage[19,50,51].
To determine the efficacy of the EGSs in inhibiting the
expression of their targets, PD4251 worms were treated
with EGS-Ngfp-lacZ, EGS-Mtgfp, a mix of EGS-Ngfp-lacZ
and EGS-Mtgfp, EGS-Ngfp-lacZ-D, EGS-Mtgfp-D, or a mix
of EGS-Ngfp-lacZ-D and EGS-Mtgfp-D. In contrast to
worms treated with soaking buffer (Fig. 2A), worms
treated with EGS-Ngfp-lacZ (Fig. 2C) or EGS-Mtgfp (Fig.
2E) showed a partial reduction in GFP fluorescence. GFP
fluorescence almost disappeared in worms treated with a
mix of EGS-Ngfp-lacZ and EGS-Mtgfp (Fig. 2G). By con-
trast, there was no decrease in GFP fluorescence in worms
treated with EGS-Ngfp-lacZ-D (Fig. 2B), EGS-Mtgfp-D
(Fig. 2D), or a mix of EGS-Ngfp-lacZ-D and EGS-Mtgfp-D
(Fig. 2F). The disabled EGSs were able to serve as negativeBMC Biotechnology 2009, 9:47 http://www.biomedcentral.com/1472-6750/9/47
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controls that cannot function effectively for RNase P-
based targeting.
The expression level of GFP mRNA was determined by
quantitative PCR (QPCR) analysis (Fig. 3A and Table 1).
Reductions of 34% and 40% in the expression level of
GFP mRNA were observed in worms treated with EGS-
Ngfp-lacZ and EGS-Mtgfp, respectively. There was a
marked reduction of 96% in the expression level of GFP
mRNA in worms treated with a mix of EGS-Ngfp-lacZ and
EGS-Mtgfp. By contrast, the expression level of GFP
mRNAs was reduced by <10% in worms treated with EGS-
Ngfp-lacZ-D, EGS-Mtgfp-D, or a mix of EGS-Ngfp-lacZ-D
and EGS-Mtgfp-D. These results indicate that these EGS-
induced significant reductions in the target mRNA expres-
sion level were due to RNase P-mediated cleavage. The
low level of inhibition in worms treated with these disa-
bled EGSs was presumably due to an anti-sense effect of
the EGS.
To examine the targeting specificity of EGS-Ngfp-lacZ and
EGS-Mtgfp, the protein levels of Ngfp and Mtgfp were
determined by Western-blot analysis (Fig. 3B and Table
1). Reductions of 56 ± 5% and less than 10% in the levels
of Ngfp and Mtgfp proteins, respectively, were observed in
worms treated with EGS-Ngfp-lacZ. Similarly, there were
reductions of 70% and less than 10% in the levels of
Mtgfp and Ngfp proteins, respectively, in worms treated
with EGS-Mtgfp. Interestingly, greater reductions of 71 ±
6% and 95% in the level of Ngfp and Mtgfp proteins,
respectively, were observed in worms treated with a mix of
EGS-Ngfp-lacZ and EGS-Mtgfp. By contrast, Ngfp and
Mtgfp protein levels were reduced by <10% in worms
treated with EGS-Ngfp-lacZ-D, EGS-Mtgfp-D or a mix of
EGS-Ngfp-lacZ-D and EGS-Mtgfp-D. The small reductions
in the Ngfp and Mtgfp protein expression levels in worms
treated with these disabled EGSs were likely due to anti-
sense effects of the EGSs.
EGSs targeted to Ngfp-lacZ and Mtgfp mRNA Figure 1
EGSs targeted to Ngfp-lacZ and Mtgfp mRNA. (A) The looped region of "auuuaaauuuuc" was chosen as a target region 
for EGS-Ngfp-lacZ. (B) The looped region of "guuaauagaauc" was chosen as a target region for EGS-Mtgfp. (C) The "3/4 EGS" 
derived form was a precursor of tRNATyr in Escherichia coli. (D, E) Complex between Ngfp-lacZ mRNA and EGS-Ngfp-lacZ (D) 
or EGS-Ngfp-lacZ-D (E). The arrow indicates the site of cleavage by RNase P. EGS-Ngfp-lacZ-D is derived from EGS-Ngfp-lacZ 
by introducing base-substitution mutations at three positions (highlighted by circles) in the T-loop. (F, G) Complexes between 
the Mtgfp mRNA and EGS-Mtgfp or EGS-Mtgfp-D, respectively. The arrow indicates the site of RNase P cleavage. EGS-Mtgfp-
D is derived from EGS-Mtgfp by introducing base-substitution mutations at three positions (highlighted by circles) of the T-
loop.BMC Biotechnology 2009, 9:47 http://www.biomedcentral.com/1472-6750/9/47
Page 4 of 20
(page number not for citation purposes)
Effects of EGS on GFP fluorescence of PD4251 worms Figure 2
Effects of EGS on GFP fluorescence of PD4251 worms. (A) Worms were treated with soaking buffer. (B, D, F) Worms 
were treated with disable EGSs (EGS-Ngfp-lacZ-D (B), EGS-Mtgfp-D (D), or a mix of EGS-Ngfp-lacZ-D and EGS-Mtgfp-D (F)). 
(C, E, G) Worms were treated with EGSs (EGS-Ngfp-lacZ (C), EGS-Mtgfp (E), or a mix of EGS-Ngfp-lacZ and EGS-Mtgfp (G)). 
To locate the nuclei, worms were stained with Hoechst 33258 stain.
Table 1: Levels of inhibition of the expression of Ngfp and Mtgfp
Treatment GFP mRNA Ngfp protein Mtgfp protein
Soaking buffer 0% 0% 0%
EGS-Ngfp-lacZ 34% 56% ± 5% 5%
EGS-Ngfp-lacZ-D 4% 6% 4%
EGS-Mtgfp 40% 5% 70%
EGS-Mtgfp-D 7% 4% 6%
Mix of EGS-Ngfp-lacZ and EGS-Mtgfp 96% 71% ± 6% 95%
Mix of EGS-Ngfp-lacZ-D and EGS-Mtgfp-D 8% 7% 8%
Inhibition of the expression of Ngfp and Mtgfp in PD4251 worms that were treated with EGS, compared with the levels of inhibition in PD4251 
worms that were treated with soaking buffer. The values shown are means derived from triplicate experiments, and values for the standard 
deviation that were less than 5% are not shown.BMC Biotechnology 2009, 9:47 http://www.biomedcentral.com/1472-6750/9/47
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Generation of EGS library
The "3/4 EGS" (Fig. 4A) was used as a framework for the
EGS library. The EGS library (Fig. 4B), which contains a
randomized anti-sense domain of the "3/4 EGS", was gen-
erated by introducing the following modifications into
the framework: the anti-sense domain was composed of
random bases; The "CCA" sequence[7,8,28,47,48] located
in the 3'-terminus is important for the EGS effect. To pro-
tect the "CCA" sequence from being exposed directly to
RNase, the "UUU" sequence was attached to its 3'-termi-
nus. The resulting EGS library is a collection that contains
any EGS targeted to any target mRNA (Fig. 4C).
pET28a-LEGS, which contains the EGS library cassette
under control of T7 promoter, was constructed (Fig. 5).
First, a primer pair of FLESp and RLEGSp was designed
(Fig. 6). The partially randomized oligonucleotides of
FLESp and RLEGSp were composed of two parts; one
acted as a primer to amplify pET28a-D equal to pET28a
but lacked the fragment between the T7 terminator and T7
promoter. The other acted as a primer to amplify the EGS
library cassette. Second, pET28a-LEGSL was amplified by
PCR with the primer pair of FLEGSp and RLEGSp using
pET28a as template. Third, pET28a-LEGS was constructed
by self-ligation of pET28a-LEGSL and transformed into
DH5α to screen for pET28a-EGS clones containing indi-
vidual EGS cassettes.
In general, about 98% of pET28a-EGS clones have one
HincII site, with the remaining 2% having two or three
(A) Effects of EGS on expression levels of GFP mRNA in PD4251 worms Figure 3
(A) Effects of EGS on expression levels of GFP mRNA in PD4251 worms. Shown is the GFP mRNA expression 
level, as measured by QPCR. (B) Effects of EGS on expression levels of Ngfp and Mtgfp proteins in PD4251 worms treated 
with EGSs. Shown are the Ngfp and Mtgfp protein expression levels, as measured by Western-blot analysis. Actin protein was 
used as an internal control.BMC Biotechnology 2009, 9:47 http://www.biomedcentral.com/1472-6750/9/47
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HincII sites. Their HincII digestion patterns were pre-
dicted by the NTI program (Fig. 7A). To examine the com-
position of the EGS library, 500 clones were chosen at
random for restriction enzyme (HincII) analysis. Of these
500 clones, 94% (Fig. 7B) showed the HincII digestion
pattern shown in Fig. 7A, lane RV1, the rest (see Addi-
tional file 1) showed the HincII digestion pattern shown
in Fig. 7A, lane RV2. Sequence analysis was performed to
determine the specific sequences; 94% were shown to
have a unique EGS cassette sequence. Alignment analysis
was used to show that these sequences (Fig. 7C) showed
no bias in cloning of certain EGS cassettes.
Validation of EGS library for reverse genetic screen in C. 
elegans
To examine whether the EGS library can be used as a
reverse genetic screen in C. elegans, 300 unique EGSs were
randomly selected and used for screening of the C. elegans
strain N2. The screening procedure is systemically shown
in Fig. 8. First, the EGS clone IVTT containing an EGS cas-
sette controlled by the T7 promoter was amplified by PCR
with the primers Fclone-IVTT and Rclone-IVTT, using the
pET28a-EGS clone as a template (Fig. 8A, B). An EGS
clone was transcribed by T7 RNA polymerase using the
purified EGS-clone IVTT as a template (Fig. 8A, C). Sec-
ond, synchronous cultures of N2 worms were soaked in
EGS solution. These worms were individually transferred
to new plates with food, and phenotypes of both P0
worms and F1 progenies were recorded (Fig. 8D). All phe-
notypes visible under the dissection microscope were
recorded. Such phenotypes included sterility, slow
postembryonic growth, larval arrest, larval lethality,
abnormal morphology, and uncoordination. About 6%
of EGSs induced abnormal phenotypes, such as P0 slow
postembryonic growth, P0 larval arrest, P0 larval lethality
and P0 sterility (Table 2). Of these, EGS-35 and EGS-83
(Fig. 9A, C) caused the greatest phenotype changes (Table
2). The target mRNAs of EGS-35 and EGS-83 were identi-
fied by the following procedure. All candidate target
mRNAs of an EGS were identified by a BLAST search of its
target sequence (see Additional file 2). BLAST searches of
all EGS-35 and EGS-83 candidate target sequences (Table
3) produced 12 and 34 candidate mRNAs (Table 4, 5),
respectively. The expression levels of all candidate target
mRNAs in worms treated with EGS-35 or EGS-83 were
analyzed by QPCR (Tables 6, 7). In worms treated with
EGS-35, there were 64% and <10% reductions in the
expression levels of ZK858.7 mRNA [Genbank:
NM_060051.2] and the other candidate mRNAs, respec-
tively. In worms treated with EGS-83, there were reduc-
tions of 72% and <10% in the expression levels of lin-13
mRNA [Genbank: NM_066277.3] and the other candi-
date mRNAs, respectively. By contrast, a reduction of
<10% in all candidate target mRNAs was observed in
worms treated with EGS-35-D or EGS-83-D (Fig. 9B, D).
These small reductions in worms treated with the disabled
EGS were likely due to anti-sense effects of the EGSs. These
results indicate that the significant reductions in the levels
of target mRNA expression (ZK858.7 mRNA and Lin-13
mRNA for EGS-35 and EGS-83, respectively) in worms
treated with EGSs were due to EGS-directed RNase-P-
mediated cleavage. The phenotypes of worms with RNAi-
ZK858.7 mRNA and RNAi-Lin-13 mRNA were similar to
the phenotypes induced by EGS-35 and EGS-83, respec-
tively (Table 2).
Demonstration of EGS library Figure 4
Demonstration of EGS library. (A) The "3/4 EGS" is derived from a precursor of tRNATyr in Escherichia coli. (B) EGS library. 
The anti-sense domain is composed of random bases. (C) The complex of EGS library and any potential target mRNA. The 
arrow indicates the RNase P cleavage site.BMC Biotechnology 2009, 9:47 http://www.biomedcentral.com/1472-6750/9/47
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Discussion
It has been shown that EGS technology can be used to
down-regulate gene expression in bacteria [9-12], mam-
malian cells [13-19] and maize cells[20]. We have shown
that EGS technology can also be used to down-regulate
gene expression in C. elegans. Several criteria must be sat-
isfied if successful EGS targeting is to be achieved. Among
these are high cleavage efficiency, EGS target specificity,
and efficient delivery of the reagent. We constructed EGS-
Ngfp-lacZ and EGS-Mtgfp that target Ngfp-lacZ and Mtgfp
mRNAs, respectively, and showed that these EGSs direct
RNase P to cleave the targets efficiently. Moreover, we
showed targeting specificity of these EGSs. Although the
complementary sequence of anti-sense domain of EGS-
Ngfp-lacZ is present in Mtgfp mRNA, a small reduction in
the Mtgfp protein expression level was observed in worms
treated with EGS-Ngfp-lacZ. In addition, Ngfp-lacZ mRNA
contains the complementary sequence of the anti-sense
domain of EGS-Mtgfp, but there was a small reduction in
the Ngfp protein expression level in worms treated with
EGS-Mtgfp. Reduction of <10% in the expression levels of
Ngfp and Mtgfp proteins were observed in worms treated
with EGS-Ngfp-lacZ-D or EGS-Mtgfp-D, respectively.
Together, these results indicate that the significant reduc-
tions in the Ngfp and Mtgfp protein expression levels in
worms that treated with EGS-Ngfp-lacZ and EGS-Mtgfp,
Construction of pET28a-LEGS. Figure 5
Construction of pET28a-LEGS. (A) Flow chart showing the construction of pET28a-LEGS. (B) The PCR product of 
pET28a-LEGSL (lane 1). The arrow indicates the 5-kb DNA band (lane M).BMC Biotechnology 2009, 9:47 http://www.biomedcentral.com/1472-6750/9/47
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respectively, were primarily due to EGS-induced RNase-P-
targeted cleavage rather than anti-sense effects or other
nonspecific effects of the EGSs. The mix of EGS-Ngfp-lacZ
and EGS-Mtgfp had greater effects on inhibition of Ngfp-
lacZ and Mtgfp expression compared with individual EGS-
Ngfp-lacZ and individual EGS-Mtgfp, respectively (Fig. 3B
and Table 1). This was probably due to anti-sense effects
of the EGSs, but is not due to any overlap in the target
sequence. Maybe the EGS methodology is particularly
effective when more than one site in a particular mRNA is
targeted[12,16].
Many C. elegans genes have been associated with pheno-
types due to the results of reverse genetic screens based on
RNAi libraries. Despite the success of these screens, the
functions of most of approximately 20,000 predicted
genes in the C. elegans genome remain elusive. Moreover,
the limitations of RNAi such as off-target [52-54] and rel-
ative variability in the RNAi effect[40] compromise the
level of confidence in the results of these RNAi screens.
The EGS library aims to facilitate reverse genetic screens
such as those with the RNAi library, and it will be useful
for confirming RNAi phenotypes. For example, ZK858.7
and lin-13 genes were identified by a reverse genetic screen
based on the EGS library. Remarkably, EGS-35 and EGS-
83 efficiently and specifically interfered with ZK858.7 and
lin-13, respectively. The target specificity of the EGS is gov-
erned by two different types of interactions[3,19]. One is
the base-pairing interactions[3,17,19,55] in which the ten
nucleotides in the EGS hybridize with the accessible
region of the target mRNA. The EGS has two short,
sequence-specific recognition elements that are oriented
in space with respect to each other in a well-defined fash-
ion. This complex recognition element provides the nec-
essary specificity for RNase P. It is known that the ten
nucleotides involved in base-pairing between the EGS and
the target mRNA make it difficult to guarantee target spe-
cificity in C. elegans. Given the extensive secondary and
tertiary structure associated with the RNA or the binding
of proteins to the target RNA in vivo, the target sequences
in cellular RNAs are not all accessible. The other type of
interaction[3,17,19,55] is between the RNase P recogni-
tion domain (e.g., T-loop and stem) and the mRNA. This
interaction facilitates the folding of the EGS-mRNA com-
plex into a tRNA-like molecule and stabilizes the mRNA-
EGS complex. An immediate corollary is that if two targets
with a one-bp mismatch are compared, the same caveat
on accessibility rules out any meaningful comment on
specificity of targeting. Mutation of a single base in the tar-
get mRNA will not affect the methodology based on "stem
EGS" because a single base mismatch in the complex with
the target mRNA is unlikely to alter recognition by RNase
P[9,12]. However, the location of the unpaired nucle-
otides is important because three contiguous unpaired
bases might very well disallow the RNase P-mediated
effects. It is that an EGS could still function despite several
point mutations between it and the bacterial target
mRNA, depending precisely on the sequence of the
unpaired bases[9]. The framework of EGS-35 and EGS-83
is the "3/4 EGS" that is distinguishable from the "stem
EGS" by additional parts equivalent to the T-stem and T-
loop, and variable regions of a tRNA. The mismatch toler-
ance of the effects of EGS-35 and EGS-83 needs further
study. Since the worms are cultured at 20°C, specificity
Demonstration of FLEGSp and RLEGSp. Figure 6
Demonstration of FLEGSp and RLEGSp. The partially randomized oligonucleotides of FLESp and RLEGSp are composed 
of two parts. One is used to amplify pET28a-D, which is equal to pET28a but does not contain the fragment between the T7 
terminator and T7 promoter. The other is used to amplify the EGS library cassette.BMC Biotechnology 2009, 9:47 http://www.biomedcentral.com/1472-6750/9/47
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Examination of composition of the EGS library Figure 7
Examination of composition of the EGS library. (A) HincII digestion patterns of the pET28a-EGS clone (lane RV1) con-
taining one HincII site, the pET28a-EGS-clone (lane RV2) containing two or three HincII sites, and pET28a (lane V). The arrow 
indicates the 5-kb DNA band (lane M). (B) The HincII digestion products of the pET28a-EGS clones containing one HincII site 
(lanes 1–42) and pET28a (lane V). The arrows indicate the 5-kb DNA band (lane M). (C) The alignment of sequences of some 
EGS cassettes.BMC Biotechnology 2009, 9:47 http://www.biomedcentral.com/1472-6750/9/47
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Table 2: Phenotypes induced by certain EGSs
EGS clone Phenotype Target Corresponding RNAi phenotype
EGS-8 sterile
EGS-26 sterile
EGS-29 slow postembryonic growth
EGS-35 slow postembryonic growth
sterile
ZK858.7 Slow growth
dumpy
sterile progeny
embryonic lethal
organism morphology abnormal
maternal sterile
transposon silencing abnormal
EGS-41 larval lethality
EGS-43 sterile
EGS-80 sterile
EGS-83 Sterile
larval arrest
Lin-13 Sterile F1
Larval arrest
sterile
multivulva
organism morphology abnormal
protruding vulva
EGS-105 larval lethality
EGS-127 slow postembryonic growth
EGS-139 slow postembryonic growth
EGS-156 sterile
EGS-189 sterile
EGS-201 larval lethality
EGS-225 slow postembryonic growth
EGS-265 larval lethality
EGS-289 sterile
EGS-296 sterile
Table 3: Candidate targeting sequences of EGS-35 and EGS-83
EGS EGS-35 EGS-83
Outline GTCGCATNNTCC GAACATANNTTG
All candidate targeting sequences GTCGCATAATCC GAACATAAATTG
GTCGCATATTCC GAACATAATTTG
GTCGCATAGTCC GAACATAAGTTG
GTCGCATACTCC GAACATAACTTG
GTCGCATTATCC GAACATATATTG
GTCGCATTTTCC GAACATATTTTG
GTCGCATTGTCC GAACATATGTTG
GTCGCATTCTCC GAACATATCTTG
GTCGCATGATCC GAACATAGATTG
GTCGCATGTTCC GAACATAGTTTG
GTCGCATGGTCC GAACATAGGTTG
GTCGCATGCTCC GAACATAGCTTG
GTCGCATCATCC GAACATACATTG
GTCGCATCTTCC GAACATACTTTG
GTCGCATCGTCC GAACATACGTTG
GTCGCATCCTCC GAACATACCTTG
The bases marked in bold are not complemented with the EGSBMC Biotechnology 2009, 9:47 http://www.biomedcentral.com/1472-6750/9/47
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considerations for antisense-based techniques are differ-
ent compared to plants/animals whose growth tempera-
tures range from 25 to 37°C.
Conclusion
EGS technology can be used to interfere with gene expres-
sion in C. elegans. The EGS library is used to facilitate a
reverse genetic screen as performed by a RNAi library, and
it should be particularly useful for confirming the RNAi
phenotype as the function of most of the approximately
20,000 predicted genes in the C. elegans genome remains
elusive. Moreover, the limitations of RNAi such as off-tar-
get and relative variability in the RNAi effect compromise
the level of confidence in the RNAi screen results. Taken
together, these observations are potentially of great
importance for further our understanding and promoting
the development of C. elegans genomics.
Methods
C. elegans, primers and vector
The N2 and PD4251 strains of C. elegans were provided by
the Caenorhabditis Genetics Center (Univ. of Minnesota,
St. Paul). The worms were maintained and handled as
described previously[56]. Primers used in this work are
listed in Table 8. The pET28a vector was purchased from
Merk, Inc.
Synchronous cultures of C. elegans
Synchronous cultures of C. elegans were prepared basically
as described previously[56]. The worms were washed well
in M9 solution (43.6 mM Na2HPO4, 22.0 mM KH2PO4,
8.6 mM NaCl, and 18.7 mM NH4Cl)[34] to completely
remove bacteria. Then, they were starved and washed well
in 0.25 × M9 solution.
Preparations of EGS-Ngfp-lacZ, EGS-Mtgfp
The EGSs that specifically target Ngfp-lacZ  or  Mtgfp
mRNAs are designed using RNA-folding software[46].
According to the rules of EGS design[28], the favorable
accessible regions of Ngfp-lacZ (Fig. 1A) and Mtgfp mRNAs
(Fig. 1B) were identified from all candidate accessible
regions. The "3/4 EGS" (Fig. 1C) was used as the design
framework. The anti-sense sequence of the accessible
region was introduced into the anti-sense domain of the
design framework. The "CCA" sequence[7,8,28,47,48]
located in the 3'-terminus is important for the EGS effect.
To protect the "CCA" sequence from being exposed
directly to RNase, the "UUU" sequence was attached to its
3'-terminus. To construct pET28a-EGS-Ngfp-lacZ and
pET28a-Mtgfp, which contain EGS-Ngfp-lacZ and EGS-
Mtgfp cassettes, respectively, under the control of the T7
promoter, primer pairs were designed using the NTI pro-
gram (see Additional file 3) and synthesized with 5'-ter-
Table 4: Candidate target mRNAs of EGS-35
Target mRNA RNAi phenotype Targeting sequence
NM_060051.2 slow_growth
dumpy
sterile_progeny
embryonic_lethal
organism_morphology_abnormal
maternal_sterile
transposon_silencing_abnormal
GTCGCATAGTCC
NM_076865.3 embryonic_lethal GTCGCATTTTCC
NM_062956.2 embryonic_lethal GTCGCATTCTCC
NM_066665.3 embryonic_lethal
locomotion_abnormal
embryonic_lethal
mitotic_spindle_abnormal_early_emb
maternal_sterile
larval_lethal
reduced_brood_size
P0_sp
GTCGCATCGTCC
NM_001029738.1 fat_content_reduced GTCGCATCCTCC
NM_072205.2 Norrmal GTCGCATTTTCC
NM_061028.1 Norrmal GTCGCATTCTCC
NM_015227.4 No record GTCGCATTTTCC
NM_001047396.2 No record GTCGCATGGTCC
NM_001047395.1 No record GTCGCATGGTCC
NM_074332.2 No record GTCGCATGGTCC
NM_068962.3 No record GTCGCATCTTCC
The accession number refers to the GenBank database.BMC Biotechnology 2009, 9:47 http://www.biomedcentral.com/1472-6750/9/47
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minal phosphorylation modification. The pET28a-EGS-
Ngfp-lacZ and pET28a-Mtgfp constructs were generated
(see Additional files 4, 5). pET28a-EGS-Ngfp-lacZL was
amplified by PCR with the primer pair of FEGSp-Ngfp-
lacZ and REGSp-Ngfp-lacZ using pET28a as a template;
the reaction conditions were 98°C for 60 s, 30 cycles of
98°C for 5 s, 70°C for 15 s and 72°C for 90 s, followed
by 72°C for 10 min, in 50-μl volumes with Phusion DNA
Polymerase (NEB: F-530S). PCR amplification of pET28a-
EGS-MtgfpL was performed as described above using the
primer pair of FEGSp-Mtgfp and REGSp-Mtgfp. The puri-
fied PCR products were self-ligated by T4 ligase (NEB) at
15°C for 16 hours. The ligation product was transformed
into DH5α-competent cells and screened with 30 μg/ml
kanamycin. The recombinant vectors of pET28a-EGS-
Ngfp-lacZ and pET28a-EGS-Mtgfp were identified by
restriction enzyme digest with HincII and sequencing
with the S-LEGS-F or S-LEGS-R primers. In vitro transcrip-
tions of EGS-Ngfp-lacZ and Mtgfp were demonstrated (see
Additional file 6). PCR amplification of EGS-Ngfp-lacZ-
IVTT was performed with the primer pair of FNgfp-lacZ-
IVTT and RNgfp-lacZ-IVTT using pET28a-EGS-Ngfp-lacZ
as a template; the reaction conditions were 98°C for 60 s,
30 cycles of 98°C for 5 s, 70°C for 15 s, and 72°C for 15
s, followed by 72°C for 10 min, in 50-μl volumes with
Phusion DNA Polymerase (NEB: F-530S). PCR amplifica-
tion of EGS-Mtgfp-IVTT was performed as described
above but using pET28a-EGS-Mtgfp as a template and the
primer pair of RMtgfp-IVTT and FMtgfp-IVTT. EGS-Ngfp-
lacZ and EGS-Mtgfp were transcribed in vitro by T7 RNA
Table 5: Candidate target mRNAs of EGS-83
Target mRNA RNAi phenotype Targeting sequence
NM_066277.3 sterile_F1
larval_arrest
sterile
multivulva
organism_morphology_abnormal
protruding_vulva
GAACATATCTTG
NM_058796.3 male_morphology_abnormal GAACATATTTTG
NM_066347.2 Abnormal: unclassified phenotypes GAACATATTTTG
NM_062293.4 Normal GAACATAAATTG
NM_070343.2 Normal GAACATAATTTG
NM_074278.2 Normal GAACATAACTTG
NM_059435.2 Normal GAACATAACTTG
NM_072012.1 Normal GAACATATTTTG
NM_059793.2 Normal GAACATATTTTG
NM_076117.3 Normal GAACATATATTG
NM_059858.2 Normal GAACATATATTG
NM_061811.2 Normal GAACATATATTG
NM_073812.2 Normal GAACATACCTTG
NM_076627.2 Normal GAACATACATTG
NM_069246.2 Normal GAACATACTTTG
NM_061292.2 Normal GAACATACTTTG
NM_063842.2 Normal GAACATAGGTTG
NM_072852.1 Normal GAACATAGTTTG
NM_066363.2 No record GAACATAAATTG
NM_001028778.1 No record GAACATAACTTG
NM_171639.2 No record GAACATATTTTG
NM_171942.1 No record GAACATATTTTG
NM_171638.2 No record GAACATATTTTG
NM_001028115.1 No record GAACATATCTTG
NM_001028116.1 No record GAACATATCTTG
NM_001028113.1 No record GAACATATCTTG
NM_001028114.1 No record GAACATATCTTG
NM_001027086.1 No record GAACATATCTTG
NM_001027085.1 No record GAACATATCTTG
NM_001029358.2 No record GAACATACATTG
NM_001029357.3 No record GAACATACATTG
NM_001029356.1 No record GAACATACATTG
NM_001028371.1 No record GAACATACTTTG
NM_001013620.3 No record GAACATAGATTG
The accession number refers to the GenBank database.BMC Biotechnology 2009, 9:47 http://www.biomedcentral.com/1472-6750/9/47
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polymerase (Epicentre) using purified PCR products of
EGS-Ngfp-IVTT and EGS-Mtgfp-IVTT, respectively, as tem-
plates.
Preparations of EGS-Ngfp-lacZ-D, EGS-Mtgfp-D, EGS-35-
D and EGS-83-D
EGS-Ngfp-lacZ-D, EGS-Mtgfp-D, EGS-35-D and EGS-83-
D were derived from EGS-Ngfp-lacZ, EGS-Mtgfp, EGS-35
and EGS-83, respectively, and contained point mutations
(5'-TTC-3' → AAG) at the three highly conserved positions
in the "T-loop" of these EGSs. These nucleotides are found
in most of the known natural tRNA sequences[49] and are
thought to be important for the interactions between the
tRNA domains and human RNase P[3]. Previous studies
have shown that EGSs with these mutations prevented
RNase P recognition and exhibited little activity in direct-
ing RNase-P-mediated cleavage[19,50,51]. EGS-Ngfp-
lacZ-D, EGS-Mtgfp-D, EGS-35-D and EGS-83-D were con-
structed according to the same strategy as described above.
For full details, see additional files 7, 8, 9, 10, 11, 12, 13,
14, 15.
Validation of effectiveness of EGS-Ngfp-lacZ and EGS-
Mtgfp
The purified EGSs were dissolved in 400 μl soaking buffer
(10.9 mM Na2HPO4, 5.5 mM KH2PO4, 2.1 mM NaCl, 4.7
mM NH4Cl, 6 mM spermidine, and 0.1% gelatin)[34].
The final RNA concentration varied from 6 to 10 mg/ml.
Synchronous cultures of C. elegans strain PD4251 (con-
taining 400 L1 larvae, 400 L2 larvae, 400 L3 larvae and
400 L4 larvae) in volumes of 400 μl 0.25 × M9 solution
were added to EGS solution and shaken at 20°C for 24
hours. The treated worms underwent the following analy-
ses: GFP fluorescence of PD4251 worms was imaged by
microscope; to locate the nuclei, and worms were stained
with Hoechst 33258 (sigma) according to standard proto-
col. Total RNA was prepared as described in the "Experi-
mental Procedures and Protocols for Total RNA Isolation"
developed and provided by Stuart Kim's laboratory. Prim-
ers for quantitative real-time PCR (QPCR) were: eft-2 (eft-
2-QPCR-F and eft-2-QPCR-R) and GFP (GFP-QPCR-F and
GFP-QPCR-R). QPCR was performed using PrimeScript™
RT reagent kit and PrimeScript®  Premix Ex Taq™ kit
(TAKARA) according to the manufacturer's instructions.
Expression level of GFP mRNA was normalized to the
mRNA eft-2 expression level. Protein was prepared accord-
ing to the "Protocol of Protein prep from C. elegans and
Western Analysis" provided by the Pasquinelli laboratory.
Western-blot analysis was performed using the following
antibodies: actin (I-19)(SANTA CRUZ sc-1616), GFP (B-
2) (SANTA CRUZ sc-9996), bovine anti-mouse IgG-AP
(SANTA CRUZ sc-2373), and donkey anti-goat IgG-AP
(SANTA CRUZ sc-2022). The films were imaged using the
UVP gel imaging analytical system (Upland, GDS-8000)
Table 6: QPCR analyses of candidate target mRNAs of EGS-35
Candidate target Primer for QPCR Inhibition level
NM_060051.2 5'-AGTCCGGTTTACTCCAAAGCAA-3' 64%
5'-CCATGAGGCTTTCCAAATGC-3'
NM_076865.3 5'-TGGCGTTGCAGATAGAATAGGA-3' 8%
5'-GCCGAAAGCGACATAACCA-3'
NM_062956.2 5'-CACCAGTAACCCAACAACTCCTAAA-3' 6 ± 5%
5'-AAGGAGAATGCGACTGGGAAG-3'
NM_066665.3 5'-TTGAGGCGAAATGCTTGTCA-3' 7%
5'-TGATGGCAAAATCGATGCA-3'
NM_001029738.1 5'-TCGGAAACCAGGCAAACAAC-3' 5%
5'-GGTCATTGTGTGCCATTTCCTT-3'
NM_072205.2 5'-TTGGTTAGAAGCGAAGTGAGTGA-3' 9%
5'-AAGGGAGGAGGAAATCAAGAGG-3'
NM_061028.1 5'-AGAGCACACGGCACATAGGA-3' 5 ± 5%
5'-CTTGTTCGGGTCTGGGTTG-3'
NM_015227.4 5'-GCACCTCAGTCTCAACATTTTCTTT-3' 7%
5'-TCACACGCCTTCTCTTGGTCT-3'
NM_001047396.2 5'-GCTCCGATTCAAGTCATGTGG-3' 7 ± 5%
5'-GCAAGCCGAAGAGGTGATGT-3'
NM_001047395.1 5'-AGGAACACCAATGGTCACAATG-3' 7%
5'-GGAACTCCGAGAGCGTAAAGCT-3'
NM_074332.2 5'-TCGTTCTGTCACGGGGAAC-3' 5 ± 6%
5'-CTTCGCATCTTTTCCACCAAC-3'
NM_068962.3 5'-CATCGTCATCTAGTCTCCCAGTGT-3' 8%
5'-TTACTTCGTTTGGTTGGTGGTG-3'
The accession number refers to the GenBank database. The values shown are means derived from triplicate experiments, and values for the 
standard deviation that were less than 5% are not shown.BMC Biotechnology 2009, 9:47 http://www.biomedcentral.com/1472-6750/9/47
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Table 7: Primer pairs for QPCR analysis candidate target mRNAs of EGS-83
Candidate target Primer for QPCR Inhibition level
NM_066277.3 5'-AATCGAAAGCTCCGTTATCCAC-3' 72%
5'-TTCCCTCGGCTTCCAAAA-3'
NM_058796.3 5'-TAAACGTGGCGGAGCTATCG-3' 5%
5'-CGTTCTCAATGCCCTTCCA-3'
NM_066347.2 5'-AAAATCATTGGTCCCGTCATG-3' 6%
5'-CCAACCAAGAAGGGCATTCA-3'
NM_062293.4 5'-AAGAGATGGATGTCTGGTAGTGGA-3' 5 ± 6%
5'-GGAAGAGAGCATCGTTTTGGA-3'
NM_070343.2 5'-AAGGACGGGAGGAACTGGA-3' 6 ± 5%
5'-TTGGGAACGAGGGAACACTT-3'
NM_074278.2 5'-ACCTTCTTGTGCCAATATTTGGA-3' 8%
5'-TTGCCATGAAGTTTCCGAAAA-3'
NM_059435.2 5'-TGGCGTCCGTTACCTTGAA-3' 6%
5'-GAATCAGCGGAGAATGCACAT-3'
NM_072012.1 5'-CCATTGGACATGGGAAAAACA-3' 5%
5'-TGGGATATTGGATTTTTGGTCAA-3'
NM_059793.2 5'-GGCACTTTTGTTGCGATTGAA-3' 6 ± 5%
5'-GGCTCTACAAGTTCCCAGCAAAT-3'
NM_076117.3 5'-TGCAATTATGGTGCACTGATAACA-3' 8%
5'-TTGCGACATTTTCGAATCGA-3'
NM_059858.2 5'-GCGATGGTATTTTTGGCAGAA-3' 6%
5'-TTCTCCGTATCCGCACTTGAA-3'
NM_061811.2 5'-TTTCAGAGTTTACCCGATGTTCAG-3' 5%
5'-CCGTATTTCCCGTAGTTTGAGG-3'
NM_073812.2 5'-CCGAAGCGTCTGTATTAGTTGCT-3' 5%
5'-TTTGACTTTTGCGGTGGATG-3'
NM_076627.2 5'-GGGAGCAGTTGTGAGAGGATTT-3' 7 ± 5%
5'-CCGCCTTCTCCGTCTTCTT-3'
NM_069246.2 5'-GCTCTGGTCGCTACTCAATCAA-3' 9%
5'-ATTACTTCCTTGTGCCTCCATCTC-3'
NM_061292.2 5'-CGCAAAACTCGGGCAAA-3' 6%
5'-GCCGTAGCCTCCATCAAAAC-3'
NM_063842.2 5'-TCGTCACATTTTCCGTTTCTCA-3' 7%
5'-GACCTGCTCCCCTGACAGTAGT-3'
NM_072852.1 5'-GGCTGAAACCAAGAACGAAAA-3' 7%
5'-TCGCAGAAGGAATGGAAGTG-3'
NM_066363.2 5'-TGAAAGCTGGCGAAGGACTT-3' 5 ± 5%
5'-CAAGGGTTTCCAACGCAAAT-3'
NM_001028778.1 5'-CGAAGCGAACGGGATAATAGTG-3' 6%
5'-CGACTCATGTGCAAGTTATGTTCTT-3'
NM_171639.2 5'-CGAGGATGTTGCCATTCAGTT-3' 7%
5'-GAAGATTTGGGTTTTCACCATGA-3'
NM_171942.1 5'-TCAGATCACTCATGAACTCCATGA-3' 5%
5'-GAAGGGCGAAAATGAGAATGAA-3'
NM_171638.2 5'-CGGTGGAAGAGATGGATGAAG-3' 6%
5'-TTCGTGATTCGGTGGAACAA-3'
NM_001028115.1 5'-GCACAACTTTATCGCAACGATTA-3' 6%
5'-GCAAAGCTGGTGCAATTCTTC-3'
NM_001028116.1 5'-CTGCCTTTGCCGATGGTTA-3' 6%
5'-CTGGATAGTAGTAGGGCTCCGAAA-3'
NM_001028113.1 5'-CTGCCTTTGCCGATGGTTA-3' 6%
5'-CTGGATAGTAGTAGGGCTCCGAAA-3'
NM_001028114.1 5'-CTGCCTTTGCCGATGGTTA-3' 6%
5'-CTGGATAGTAGTAGGGCTCCGAAA-3'
NM_001027086.1 5'-GGAGCGCGTCAGAGTAAACG-3' 7%
5'-TTTCGAGACGGCCTTTGTTC-3'
NM_001027085.1 5'-GGAGCGCGTCAGAGTAAACG-3' 7%
5'-TTTCGAGACGGCCTTTGTTC-3'
NM_001029358.2 5'-ATGCATATTGAGCACGCAGAA-3' 5%
5'-CGGGCAGATGCAATTGTTT-3'BMC Biotechnology 2009, 9:47 http://www.biomedcentral.com/1472-6750/9/47
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NM_001029357.3 5'-CGAGAGCGGCGAGTTGATAG-3' 5%
5'-ATACTGCATCCGAGCAACATGT-3'
NM_001029356.1 5'-CGAGAGCGGCGAGTTGATAG-3' 5%
5'-ATACTGCATCCGAGCAACATGT-3'
NM_001028371.1 5'-CCCAAATGTTATGCCAGTCAAG-3' 5%
5'-TTGGAAGATGTAGAATGGTGAGAGA-3'
NM_001013620.3 5'-CAGACTTCCACCTATTAAAGGACCA-3' 7%
5'-CACAAAACAGAAATCCCAGAAGG-3'
The accession number refers to the GenBank database. The values shown are means derived from triplicate experiments, and values for the 
standard deviation that were less than 5% are not shown.
Table 7: Primer pairs for QPCR analysis candidate target mRNAs of EGS-83 (Continued)
Reverse genetic screen of C. elegans based on EGS Figure 8
Reverse genetic screen of C. elegans based on EGS. (A) The flow chart of EGS-clone preparation. (B) The PCR product 
of the EGS clone IVTT (lanes 1–7). The arrow indicates the 750-bp DNA band (lane M). (C) The transcription product of the 
EGS clone (lanes 1–7). The arrow indicates the 100-bp RNA band (lane M). (D) Diagram of the phenotype screening proce-
dure.BMC Biotechnology 2009, 9:47 http://www.biomedcentral.com/1472-6750/9/47
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and analyzed using Labworks software. Actin protein was
used as an internal control.
Construction of EGS library
To construct pET28a-LEGS, which contains the EGS
library cassette under control of the T7 promoter, the
primer pair of FLEGSp and RLEGSp was designed using
the NTI program and synthesized with random bases at
certain positions and 5'-terminal phosphorylation modi-
fications. pET28a-LEGSL was amplified by PCR with the
primer pair of FEGSp and REGSp using pET28a as a tem-
plate; the reaction conditions were 98°C for 60 s, 30
cycles of 98°C for 5 s, 70°C for 15 s and 72°C for 90 s,
followed by 72°C for 10 min, in 50-μl volumes with Phu-
sion DNA Polymerase (NEB: F-530S). One microgram of
the purified PCR product of pET28a-LEGSL was self-
ligated by T4 ligase (NEB) in a 1-ml volume at 15°C for
16 hours. The ligation product was purified and trans-
formed into DH5α maximum efficiency competent cells
(Invitrogen: 18258-012), and selection of bacterial clones
was performed with 30 μg/ml kanamycin. Individual
clones were selected at random for restriction enzyme
digest with HincII and sequencing with the S-LEGS-F or S-
LEGS-R primers.
Reverse genetic screen based on EGS
PCR amplification of the EGS clone IVTT was performed
with the primer pair of Fclone-IVTT and Rclone-IVTT
using the pET28a-EGS clone as a template; the reaction
conditions were: 98°C for 60 s, 30 cycles of 98°C for 5 s,
70°C for 15 s and 72°C for 15 s, followed by 72°C for 10
min, in 50-μl volume with Phusion DNA Polymerase
(NEB: F-530S). The EGS clone was transcribed in vitro
using T7 RNA polymerase (Epicentre) and the purified
PCR product of the EGS clone IVTT as a template. The
purified EGS clone was dissolved in 4 μl soaking buffer
(10.9 mM Na2HPO4, 5.5 mM KH2PO4, 2.1 mM NaCl, 4.7
mM NH4Cl, 6 mM spermidine, and 0.1% gelatin)[34].
The final RNA concentration varied from 6 to 10 mg/ml.
Purified synchronous cultures of C. elegans strain N2 (con-
taining 3 L1 larvae, 3 L2 larvae, 3 L3 larvae and 3 L4 lar-
vae) in a volume of 4 μl 0.25 × M9 solution were added to
each EGS solution in 48-well PCR plates and shaken at
20°C for 24 hours. The worms were then transferred to
new plates with food and phenotypes of both P0 worms
and F1 progenies were recorded.
Identification of target mRNA of EGS-35 and EGS-83
All candidate target mRNAs of an EGS were identified by
BLAST analysis of the target sequence (see Additional file
2). The expression levels of all candidate target mRNAs in
worms treated with EGS-35 or EGS-83 were analyzed by
QPCR as described above. Primers for QPCR are listed in
Tables 6, 7 and 8. Expression levels of candidate target
mRNA were normalized to the expression level of the
mRNA eft-2.
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Complexes between candidate target mRNAs and EGS-35, EGS-35-D, EGS-83, EGS-83-D Figure 9
Complexes between candidate target mRNAs and EGS-35, EGS-35-D, EGS-83, EGS-83-D. (A, B) Complexes 
between a candidate target mRNA and EGS-35 (A) and EGS-35-D (B). The arrow indicates the RNase P cleavage site. EGS-35-
D was derived from EGS-35 by introducing base-substitution mutations at three positions (highlighted by circles) of the T-loop. 
(C, D) Complexes between a candidate target mRNA and EGS-83 (C) and EGS-83-D (D). The arrow indicates the RNase P 
cleavage site. EGS-83-D was derived from EGS-83 by introducing base-substitution mutations at three positions (highlighted by 
circles) of the T-loop.BMC Biotechnology 2009, 9:47 http://www.biomedcentral.com/1472-6750/9/47
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Table 8: Primers used in this study
Primer Sequence
FLEGSp 5'-pTCGATGACGGCAGATTTAGAGTCTGCTNNNTTTGGCTATAGTGAGTCGTATTAATTTCG-3'
RLEGSp 5'-pCTTCGAAGGTTCGAATCCTTCNNNNNNNACCATTTTAGCATAACCCCTTGGGGCCTCT-3'
FEGSp-Ngfp-lacZ 5'p-TCGATGACGGCAGATTTAGAGTCTGCTTTCTTTGGCTATAGTGAGTCGTATTAATTTCG-3'
REGSp-Ngfp-lacZ 5'p-CTTCGAAGGTTCGAATCCTTCTTTAAATACCATTTTAGCATAACCCCTTGGGGCCTCT-3'
FEGSp-Mtgfp 5'p-TCGATGACGGCAGATTTAGAGTCTGCTATCTTTGGCTATAGTGAGTCGTATTAATTTCG-3'
REGSp-Mtgfp 5'p-CTTCGAAGGTTCGAATCCTTCTATTAACACCATTTTAGCATAACCCCTTGGGGCCTCT-3'
FEGSp-Ngfp-lacZ-D 5'p-TCGATGACGGCAGATTTAGAGTCTGCTTTCTTTGGCTATAGTGAGTCGTATTAATTTCG-3'
REGSp-Ngfp-lacZ-D 5'p-CTTCGAAGGAAGGAATCCTTCTTTAAATACCATTTTAGCATAACCCCTTGGGGCCTCT-3'
FEGSp-Mtgfp-D 5'p-TCGATGACGGCAGATTTAGAGTCTGCTATCTTTGGCTATAGTGAGTCGTATTAATTTCG-3'
REGSp-Mtgfp-D 5'p-CTTCGAAGGAAGGAATCCTTCTATTAACACCATTTTAGCATAACCCCTTGGGGCCTCT-3'
FLEGSp-35-D 5'-pTCGATGACGGCAGATTTAGAGTCTGCTTCCTTTGGCTATAGTGAGTCGTATTAATTTCG-3'
RLEGSp-35-D 5'-pCTTCGAAGGAAGGAATCCTTCATGCGACACCATTTTAGCATAACCCCTTGGGGCCTCT-3'
FLEGSp-83-D 5'-pTCGATGACGGCAGATTTAGAGTCTGCTTTGTTTGGCTATAGTGAGTCGTATTAATTTCG-3'
RLEGSp-83-D 5'-pCTTCGAAGGAAGGAATCCTTCTATGTTCACCATTTTAGCATAACCCCTTGGGGCCTCT-3'
Fclone-IVTT 5'-AAATGGTNNNNNNNGAAG-3'
Rclone -IVTT 5'-AGATTGTGCACCGCCGCT-3'
FNgfp-lacZ-IVTT 5'-AAATGGTATTTAAAGAAGGA-3'
RNgfp-lacZ-IVTT 5'-AGATTGTGCACCGCCGCT-3'
FMtgfp-IVTT 5'-AAATGGTGTTAATAGAAGGA-3'
RMtgfp-IVTT 5'-AGATTGTGCACCGCCGCT-3'
F35-IVTT 5'-AAATGGTGTCGCATGAAG-3'
R35 -IVTT 5'-AGATTGTGCACCGCCGCT-3'
F83-IVTT 5'-AAATGGTGAACATAGAAG-3'
R83 -IVTT 5'-AGATTGTGCACCGCCGCT-3'
eft-2-QPCR-F 5'-GACGAGAAGGATTTGGAAGGAA-3'
eft-2-QPCR-R 5'-ACTGGGGATGGAAGATGGAA-3'
GFP-QPCR-F 5'-TGGAGTTGTCCCAATTCTTGTT-3'
GFP-QPCR-R 5'-GCATCACCTTCACCCTCTCC-3'
S-EGS-F 5'-TTAGAGCTTGACGGGGAAAG-3'
S-EGS-R 5'-CCTGCCACCATACCCACGCC-3'
The "p" in the "sequence" column represents the modification by phosphorylation. Fclone-IVTT is the outline of the corresponding primer used in 
the specific experiment. Base-substitution mutations at three positions of the T-loop are indicated by bold text.BMC Biotechnology 2009, 9:47 http://www.biomedcentral.com/1472-6750/9/47
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Additional material
Additional File 1
HincII digestion pattern. The HincII digestion products of the pET28a-
EGS clone (lane 1) containing two or three HincII sites, the pET28a-EGS 
clones (lanes 2–6) containing one HincII site, and pET28a (lane V). The 
arrow indicates the 5-kb DNA band (lane M).
Click here for file
[http://www.biomedcentral.com/content/supplementary/1472-
6750-9-47-S1.tiff]
Additional File 2
All candidate target mRNAs of an EGS were identified by BLAST 
analysis of the target sequence. The NCBI-BLAST web interface.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1472-
6750-9-47-S2.tiff]
Additional File 3
Demonstration of primer pair. (A) The primer pair of FEGSp-Ngfp-lacZ 
and REGSp-Ngfp-lacZ. The partially randomized oligonucleotides of 
FEGSp-Ngfp-lacZ and REGSp-Ngfp-lacZ were composed of two parts. 
One was used to amplify pET28a-D, which is equal to pET28a but with-
out the fragment between the T7 terminator and T7 promoter. The other 
was used to amplify the EGS-Ngfp-lacZ cassette. (B) The primer pair of 
FEGSp-Mtgfp and REGSp-Mtgfp. The partially randomized oligonucle-
otides of FEGSp-Mtgfp and REGSp-Mtgfp were composed of two parts. 
One was used to amplify pET28a-D; the other was used to amplify EGS-
Mtgfp cassette.
Click here for file
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Additional File 4
Construction of pET28a-EGS-Ngfp-lacZ. (A) Flow chart showing con-
struction of pET28a-EGS-Ngfp-lacZ. (B) The PCR product of pET28a-
EGS-Ngfp-lacZL (lane 1). The arrow indicates the 5-kb DNA band (lane 
M).
Click here for file
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6750-9-47-S4.tiff]
Additional File 5
Construction of pET28a-EGS-Mtgfp. (A) Flow chart showing pET28a-
EGS-Mtgfp construction. (B) The PCR product of pET28a-EGS-MtgfpL 
(lane 1). The arrow indicates the 5-kb DNA band (lane M).
Click here for file
[http://www.biomedcentral.com/content/supplementary/1472-
6750-9-47-S5.tiff]
Additional File 6
Preparations of EGS-Ngfp-lacZ and EGS-Mtgfp. (A) Flow chart show-
ing preparation of EGS-Ngfp-lacZ. (B) Flow chart showing preparation of 
EGS-Mtgfp. (C) The PCR products of IVTT-EGS-Ngfp-lacZ (lane 1) and 
IVTT-EGS-Mtgfp (lane 2). The arrow indicates the 750-bp DNA band 
(lane M). (D) The transcription products of EGS-Ngfp-lacZ (lane 1) and 
EGS-Mtgfp (lane2). The arrow indicates the 100-bp RNA band (lane 
M).
Click here for file
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6750-9-47-S6.tiff]
Additional File 7
Demonstration of primer pair. (A) The primer pair of FEGSp-Ngfp-
lacZ-D and REGSp-Ngfp-lacZ-D. The partially randomized oligonucle-
otides of FEGSp-Ngfp-lacZ-D and REGSp-Ngfp-lacZ-D were composed of 
two parts. One was used to amplify pET28a-D, which is equal to pET28a 
but without the fragment between the T7 terminator and T7 promoter. 
The other was used to amplify the EGS-Ngfp-lacZ-D cassette. (B) The 
primer pair of FEGSp-Mtgfp-D and REGSp-Mtgfp-D. The partially rand-
omized oligonucleotides of FEGSp-Mtgfp-D and REGSp-Mtgfp-D were 
composed of two parts. One was used to amplify pET28a-D; the other was 
used to amplify EGS-Mtgfp-D cassette.
Click here for file
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6750-9-47-S7.tiff]
Additional File 8
Demonstration of primer pair. (A) The primer pair of FEGSp-35-D and 
REGSp-35-D. The partially randomized oligonucleotides of FEGSp-35-D 
and REGSp-35-D were composed of two parts. One was used to amplify 
pET28a-D, which is equal to pET28a but without the fragment between 
the T7 terminator and T7 promoter. The other was used to amplify the 
EGS-35-D cassette. (B) The primer pair of FEGSp-83-D and REGSp-83-
D. The partially randomized oligonucleotides of FEGSp-83-D and 
REGSp-83-D were composed of two parts. One was used to amplify 
pET28a-D; the other was used to amplify the EGS-83-D cassette.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1472-
6750-9-47-S8.tiff]
Additional File 9
Construction of pET28a-EGS-Ngfp-lacZ-D. (A) Flow chart showing 
construction of pET28a-EGS-Ngfp-lacZ-D. (B) The PCR product of 
pET28a-EGS-Ngfp-lacZ-DL (lane 1). The arrow indicates the 5-kb DNA 
band (lane M).
Click here for file
[http://www.biomedcentral.com/content/supplementary/1472-
6750-9-47-S9.tiff]
Additional File 10
Construction of pET28a-EGS-Mtgfp-D. (A) Flow chart showing con-
struction pET28a-EGS-Mtgfp-D. (B) The PCR product of pET28a-EGS-
Mtgfp-DL (lane 1). The arrow indicates the 5-kb DNA band (lane M).
Click here for file
[http://www.biomedcentral.com/content/supplementary/1472-
6750-9-47-S10.tiff]
Additional File 11
Preparations of EGS-Ngfp-lacZ-D and EGS-Mtgfp-D. (A) Flow chart 
showing preparation of EGS-Ngfp-lacZ-D. (B) Flow chart showing prep-
aration of EGS-Mtgfp-D. (C) The PCR products of IVTT-EGS-Ngfp-lacZ-
D (lane 1) and IVTT-EGS-Mtgfp-D (lane 2). The arrow indicates the 
750-bp DNA band (lane M). (D) The transcription products of EGS-
Ngfp-lacZ-D (lane 1) and EGS-Mtgfp-D (lane2). The arrow indicates 
the 100-bp RNA band (lane M).
Click here for file
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